Allogene Therapeutics, Inc. (ALLO)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
ALLO trades thinly or has a short history, so some panels below have little to show.
Follow ALLO in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ALLO and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ALLO at a glance
Key statistics
$459.50M
Market capitalization
- Previous close
- $1.33
- Open
- $1.33
- Day range
- $1.31 – $1.37
- Volume
- 4.73M
- Average volume (30 sessions)
- 5.76M
- Shares outstanding
- 345.49M
- Earnings per share
- $(0.48)
- Price / book
- 1.1
- Price / sales
- 99.0
- Beta (1 year, vs SPY)
- 1.88
Where the price sits in its year
52-week range
8% of the range
- Below the 52-week high
- -70.2%
- Above the 52-week low
- +27.9%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $1.45-8.5%
- 50-day average
- $1.74-23.4%
- 200-day average
- $1.99-33.2%
Between the conventional 30 and 70 bands.
+2.3%
1 week
-22.2%
1 month
-26.9%
3 months
-2.9%
Year to date
+3.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ALLO
ALLO on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ALLO.
See the plans →
Every planScreen names like ALLO
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ALLO
Put ALLO on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ALLO
See whether there is an open premium alert on ALLO, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ALLO headlines
- Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc. · Apr 14, 2026
- Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Benzinga · Dec 16, 2025
- Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
GlobeNewswire Inc. · Dec 15, 2025
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
GlobeNewswire Inc. · Jun 1, 2025
- Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
GlobeNewswire Inc. · Jul 1, 2024
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
GlobeNewswire Inc. · Jun 20, 2024
- Analyst Ratings For Allogene Therapeutics
Benzinga · May 31, 2024
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
GlobeNewswire Inc. · May 23, 2024
SEC Form 4, most recent first
Insider filings
Douglas Earl Martin
−29.7K
SVP, General Counsel · Open-market sale
$62.96K · Aug 21, 2026
Roberts Zachary
+134.5K
President and CEO · Grant or award
· Jul 1, 2026
Roberts Zachary
+476.2K
President and CEO · Grant or award
· Jul 1, 2026
Kazam Joshua A
−47.7K
Director · Option exercise
· Jun 18, 2026
WITTE OWEN N.
+95.4K
Director · Grant or award
· Jun 18, 2026
Kazam Joshua A
+95.4K
Director · Grant or award
· Jun 18, 2026
MESSEMER DEBORAH M.
+95.4K
Director · Grant or award
· Jun 18, 2026
Kazam Joshua A
+47.7K
Director · Option exercise
· Jun 18, 2026
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Employees
- 152
- Listed since
- Oct 11, 2018
- Website
- allogene.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.